San Diego – October 21, 2016 – Cooley advised Cidara Therapeutics on its $27.8 million follow-on offering.
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.
Cooley advised Cidara on its IPO in 2015.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.